Sun 5/31/2020 12:37 ET
DJIA25383.1117.770.07%TELCO171.241.971.15%GOLD1731.6018.351.06%Shanghai2852.356.280.22%
S&P 5003044.3114.610.48%BANKS337.628.812.61%OIL35.341.634.61%BITCOIN9371.6160.920.65%
NASDAQ9489.87122.421.29%PHARM616.736.110.99%US/EU1.110.000.00%Futures3057.2519.260.63%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Keryx Biopharmaceuticals - KERX   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add KERX
  
From: SpecGuru (Rep: 63) reply to SpecGuruDate: 09/22/2016 15:51
Forum: Keryx Biopharmaceuticals - Msg #2606Thread #673868708 (Rec: 0)
Enjoying? ^^ The problem for shorts is they must compete with each other and the pipe is not wide enough not to cause squeezes. I expect $7 soon, maybe at the announcement of a simple "problem solved!" which "will" be solved anyway in the next two months. Re: This will be the third presentation this month. Company is working hard! BOS...



*****I am writing drunk*****



Reply to SpecGuru - Msg #2605 - 09/21/2016 15:30

This will be the third presentation this month. Company is working hard! BOSTON , Sept. 21, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc , (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast its corporate presentation at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27 at 4:00 p.m. Eastern Time .
A live audio webcast of the presentation will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals , with headquarters in Boston , is focused on bringing innovative medicines to people with renal disease. In December 2014 , the company launched its first FDA -approved medicine, Auryxia® (ferric citrate) in the United States. In January 2014 , ferric citrate was approved for use in Japan , where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015 , the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). For more information about Keryx, please visit www.keryx.com.
Re: From Chris Lau in Valuestocks "...Kerx Biopharmaceuticals Will Rebound,
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser SpecGuru: Reward | Watch | IgnoreKERX: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add KERX
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.